Is PGEN Worth Buying in 2026?

Precigen, Inc. Common Stock

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-06-07

Here’s whether Precigen, Inc. Common Stock (PGEN) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.

🟡
Caution

Positives: 50-day MA is rising (+3.96% over 10 days); strong 1-year return of +169.2%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); RSI 28 — oversold; rising volume on a downtrend (distribution, 1.37x avg). Currently 34.5% off its 52-week high. Score: -2/7.

Ready to act on this? 📈 Trade on Webull

PGEN is trading below its 200-day MA ($4.02) — a key warning sign the longer-term trend is under pressure. An RSI of 27.9 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of +169.2% compares to +24.4% for SPY (beat the market by 144.8%). The current 34.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $26,917 today
vs. S&P 500 (SPY) — same period beat market by 144.8%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($4.02)
Above 50-day MA ($4.09)
!RSI(14) neutral zone (30–70) — currently 27.9
Positive return (+169.2%)
!Within 10% of period high (−34.5%)
Period Range $3.58
$1.30 $5.47
RSI (14) 27.9
0 · OversoldOverbought · 100

Key Metrics

Price$3.58
Period Return+169.2%
Period High$5.47
Period Low$1.30
Drawdown−34.5%
MA-50$4.09
MA-200$4.02
RSI (14)27.9
Avg Volume (30d)4.1M
vs. SPYbeat by 144.8%
Return Rank#113 of 1245

Trade PGEN

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers